PARP Inhibitor Stage I-III Breast Cancer Trials
PARP Inhibitor Trials for People with Stage I-III Breast Cancer
The below studies are PARP inhibitor studies that are currently enrolling patients with early stage (I-III) breast cancer. For more details on an individual study, please contact the study coordinator or visit clinicaltrials.gov.
- NCT01074970: PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)or BRCA1/2 Mutations
- NCT00813956: A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (PARP Inhibitor also known as iniparib) in the Neoadjuvant Treatment of Triple Negative Breast Cancer
- NCT01042379: I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Page updated 08/31/11
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.